IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone407-677-8022
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.44 million
Profitability
Miscellaneous
Employees95
Next Earnings Date10/30/2019 (Confirmed)
OptionableNot Optionable
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) posted its quarterly earnings results on Tuesday, July, 30th. The medical equipment provider reported $0.17 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.12 by $0.05. The medical equipment provider had revenue of $9.23 million for the quarter, compared to the consensus estimate of $8.91 million. Iradimed had a net margin of 23.92% and a return on equity of 14.78%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
How can I listen to Iradimed's earnings call?
Iradimed will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Iradimed issued on next quarter's earnings?
Iradimed issued an update on its third quarter 2019 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of $0.14-0.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.16. The company issued revenue guidance of $9.7-10 million, compared to the consensus revenue estimate of $9.84 million.
Has Iradimed been receiving favorable news coverage?
Media coverage about IRMD stock has trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Iradimed earned a news impact score of 0.8 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Iradimed.
Are investors shorting Iradimed?
Iradimed saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 427,200 shares, a decline of 5.2% from the August 15th total of 450,600 shares. Based on an average daily volume of 79,700 shares, the short-interest ratio is currently 5.4 days. Currently, 7.9% of the shares of the company are short sold. View Iradimed's Current Options Chain.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include Orthofix Medical (OFIX), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD), Luminex (LMNX), Cryolife (CRY), Anika Therapeutics (ANIK), LeMaitre Vascular (LMAT), Cerus (CERS), SurModics (SRDX), Axonics Modulation Technologies (AXNX), AngioDynamics (ANGO), Antares Pharma (ATRS), MiMedx Group (MDXG), Orthopediatrics (KIDS) and Intersect ENT (XENT).
What other stocks do shareholders of Iradimed own?
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
- Mr. Christopher K. Scott, CFO & Sec. (Age 49)
- Mr. John McCreery, Chief Operating Officer (Age 64)
- Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
- Mr. Louis Waldman, Controller (Age 64)
Who are Iradimed's major shareholders?
Iradimed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Roubaix Capital LLC (0.58%) and Navellier & Associates Inc (0.25%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.
Which major investors are selling Iradimed stock?
IRMD stock was sold by a variety of institutional investors in the last quarter, including Navellier & Associates Inc. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.
Which major investors are buying Iradimed stock?
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $23.08.
How big of a company is Iradimed?
Iradimed has a market capitalization of $262.42 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.View Additional Information About Iradimed.
What is Iradimed's official website?
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
